Nab-paclitaxel

FDA’s June 2024 list of off-patent, off-exclusivity drugs sees rise in cancer, HIV treatments

This week PharmaCompass brings to you key highlights of the US Food and Drug Administration’s

Top drugs and pharmaceutical companies of 2019 by revenues

Acquisitions and spin-offs dominated headlines in 2019 and the tone was set very early with Bristol-

GSK’s overhaul begins under new CEO; Sandoz loses US$ 940 million lawsuit

This week, Phispers brings you news on GSK, whose new CEO is planning a slew of initiatives to make

GSK, Google form first bioelectronics firm; 11 generic companies benefit from the Teva Allergan deal

This week, Phispers brings to you the details of the bioelectronics firm formed by GSK and Google. T

Marijuana Based Medicines – highway to pots of gold

Legally cultivated cannabis, in some parts of the United States, resulted in a boom, which could ne

Dr. Reddy’s expansion plans for API production

Unrelated to the inspection of the USFDA at the Dr. Reddys Srikakulam facility, Dr. Reddys sought pe

Cabazitaxel –The Market Overcrowding Begins

Many companies have been actively developing Cabazitaxel (Jevtana Kit®), a prostate cancer drug